Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy ...

For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved ...

Treatment for lung cancer has changed significantly with immunotherapy, an expert said during the CURE® Educated Patient® ...

For such a common disease, lung cancer can be hard to spot. In the early stages you probably won't even know you've got a ...

“Such a combination is also approved for the management of advanced PD-L1-positive lung cancers. The same combination along with chemotherapy is also approved for all types of lung ...

Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung cancer, based on results from a small clinical trial led ...

Practice-changing studies in advanced non-small cell lung cancer presented at ASCO 2024 are reviewed by Dr Ticiana Leal, ...

Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support standard use of the ...

Matthew Triplette, Fred Hutchinson Cancer Center and University of Washington, Seattle, USA, delivered an insightful ...

Our findings show it's time to routinely adopt IMRT over 3D-CRT for lung cancer, just like we did for prostate, anal and brain tumors decades ago. The improved precision of IMRT translates into real ...

“The results from HERTHENA-Lung01 provide compelling evidence of efficacy of patritumab deruxtecan in heavily pretreated ...

The following is a summary of “Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced ...